Skip to content

Continuous Interscalene Blocks and Rebound Pain

Evaluation of the Effect of Continuous Interscalene Blocks on Rebound Pain Compared to Single-Shot Interscalene Blocks in Total Shoulder Arthroplasty : A Randomized-Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07770165
Enrollment
154
Registered
2026-08-18
Start date
2026-10-01
Completion date
2027-05-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Interscalene Analgesia, Interscalene Blocks, Interscalene Nerve Block, Orthopedic Surgery Patients, Locoregional Anaesthesia, Rebound Pain

Keywords

Interscalene, Nerve Block, Catheter, Continuous Interscalene Block, Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Rebound Pain

Brief summary

The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty. Rebound pain has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance."

Detailed description

The number of patients requiring shoulder replacements for many different indications, including osteoarthritis, cuff arthropathy and acute fractures has continually grown in the last 15 years, as suggested by a recent international meta-analysis. While there is no designated Canadian database specific to total shoulder arthroplasty compiled by the Canadian Institute for Health Information (CIHI), international data suggests that the expansion of the indications for reverse total shoulder replacements has contributed to the increase in the total amount of patients that undergo such procedure, with an estimated growth of 6-15% between 2011 and 2019. Moreover, there has also been a four-fold increase in the proportion of outpatient shoulder arthroplasty cases in an ACS-NSQIP database from 2015-2019, without a notable increase in adverse patient events, highlighting a shift towards a more ambulatory approach to total shoulder arthroplasty (TSA). As this procedure becomes mostly ambulatory, new challenges arise regarding the best pain management modality to limit the overall need for opioids and reduce their side effects including respiratory depression, pruritis, nausea and vomiting, as well as increasing patient satisfaction and recovery. There are multiple anesthetic techniques described in the literature to aid in multimodal analgesia, the most commonly used being the interscalene block (ISB), as a single-shot (sISB) or as a continuous infusion (cISB), often combined with multimodal analgesia with dexamethasone and dexmedetomidine. Other techniques include superior trunk blocks, as well as suprascapular nerve block, often used as an alternative when respiratory complications are a major concern due to phrenic nerve blockade. Most regional analgesia techniques detailed above have shown superior pain management compared to local infiltration alone. Although the interscalene block is clearly established as standard of care for all patients undergoing shoulder surgery, numerous studies have compared the efficacy of sISB versus catheter-based cISB, with variable results favoring either modality in terms of pain management, opioid consumption and patient-related side effects. A more recent systematic review and meta-analysis of over 1000 patients in 20 trials on the effects of single-injection vs. continuous brachial plexus blocks for shoulder surgeries on patient-reported outcomes published in June 2026 has highlighted better pain management for cISB than sISB, especially during the 12- to 48-hour period, although most of the regimens showing better analgesia also included patient-controlled boluses. Notably, mean pain at rest was lower in the cISB group, with a particular benefit in the 24-48 hour period, a period where the concept of "rebound pain" can occur with single-shot modalities. This concept has been defined in some studies as the "the transition from well-controlled pain (numerical rating scale \[NRS\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance.", with an estimated occurrence of 49.6%. Some identified contributors were younger patients, female gender, surgery involving bone, the absence of IV dexamethasone, as well as upper limb surgery. A possible explanation relies on a "supply-vs-demand" mismatch, where the possible analgesic block could be of insufficient length compared to the patient's needs, especially in the at-risk populations. A study realized in 2007 on femoral nerve block proved that prolonging a nerve block with a catheter based infusion did reduce the apparition of rebound pain. This concept has yet to be formally evaluated in upper limb surgeries and blocks, including in total shoulder arthroplasty.

Interventions

This Interventional Group will receive a continuous interscalene block via a catheter for a duration of 48 hours with ropivacaine 0.2% at a fixed 5 mL/hour rate.

DRUGInterscalene Block

This control group will receive a single shot interscalene block with 20 mL of ropivicaine 0.2%.

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The anesthesiologist responsible for block or catheter placement, the attending anesthesiologist, surgeons, and patients will not be blinded to their intervention. However, the responsible party for conducting postoperative follow-up phone assessments at 24, 48, 72, and 96 hours will be blinded to treatment allocation.

Intervention model description

This is a pragmatic randomized controlled, parallel group, single-blinded trial comparing a single-shot interscalene block (control group) to a catheter-based continuous interscalene block (treatment group) placed preoperatively in total shoulder arthroplasty patients.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged \>18 years of age * ASA I-III * Scheduled for elective ambulatory total shoulder arthroplasty.

Exclusion criteria

* ASA IV * Revision surgery * Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection) * Preoperative chronic pain or opioid use * Preoperative drug dependency * Severe respiratory disease or contralateral diaphragmatic paralysis * Patient refusal.

Design outcomes

Primary

MeasureTime frameDescription
incidence of Rebound pain within 96 hours postoperativelyThis outcome will be measured within 24 hours of block resolution, for up to 96 hours after the initial block realization.The incidence of Rebound Pain, defined as an NRS score of \< 3 during an effective block to an NRS \> 7 within 24 hours of block resolution. This will be analyzed as a binary variable (yes/no)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026